FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Wasiiiigton, D.C. 20049	OMB APPROVAL		
TEMENT OF CHANGES IN BENEFICIAL OWNERSHIP	OMB Number:	3235	

Estimated average burden hours per response: Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

0.5

	Check this box if no longer subject to
\Box	Section 16. Form 4 or Form 5
\cup	obligations may continue. See
	Instruction 1(b).

			or Section 30(h) of the Investment Company Act of 1940								
1. Name and Address of Reporting Person* McGowan Kathleen A			2. Issuer Name and Ticker or Trading Symbol DISCOVERY LABORATORIES INC /DE/ [DSCO]		ationship of Reporting Person(s) to Issuer k all applicable) Director 10% Owner Officer (give title Other (specify below)						
(Last) (First) (2600 KELLY DRIVE SUITE 100		(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 01/03/2006		Dir, Finance and Controller						
(Street) WARRINGTON (City)	PA (State)	18976 (Zip)	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indivi Line) X	idual or Joint/Group Filing (0 Form filed by One Reporti Form filed by More than C Person	ing Person					
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned											

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transa Code (I 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(msu. 4)
Common Stock ⁽¹⁾	07/21/2005		A	V	271	A	\$6.461	803	D	
Common Stock ⁽¹⁾	10/21/2005		A	V	271	A	\$6.45	1,074	D	
Common Stock ⁽²⁾	01/03/2006		A		2,500	A	\$0	3,574	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		of Exp		Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Incentive Stock Option (right to	\$7.01	01/03/2006		A		20,000		01/03/2006	01/03/2016	Common Stock	20,000	\$0	20,000	D	

Explanation of Responses:

- $1.\ Transaction\ reported\ on\ Table\ I\ represents\ Issuer's\ matching\ stock\ contribution\ pursuant\ to\ 401(k)\ plan.$
- 2. New restricted stock award shall fully vest on the date that Surfaxin for RDS first becomes widely commercially available, as such date is determined by the Company.
- 3. This employee stock option shall vest 25% on the date of the grant, and the balance shall vest in a series of three successive equal annual installments beginning with the first year anniversary of the grant.

Kathleen A. McGowan

01/05/2006

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.